Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Synklino A/S is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, KAUFMAN, CLAIRE M, within a distinct art unit. The prosecution landscape for the company is currently defined by this pending office action.
As KAUFMAN, CLAIRE M is the only examiner involved, the company's immediate efforts are concentrated on this 1 pending case. The presence of only 1 pending office action reflects a targeted prosecution strategy for the company's current biotechnology portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279907 | COMPOSITIONS FOR EX VIVO ORGAN CARE | KAUFMAN, CLAIRE M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279907 | COMPOSITIONS FOR EX VIVO ORGAN CARE | KAUFMAN, CLAIRE M | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18279907 | COMPOSITIONS FOR EX VIVO ORGAN CARE | KAUFMAN, CLAIRE M | 1674 | §102§103§112Other | Non-Final OA | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSynklino A/S has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Claire M Kaufman has the most, with 1 of Synklino A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
